Dr. Charles J. Lockwood is Executive Vice President (EVP) for USF Health, Dean of the Morsani College of Medicine and Professor of Obstetrics & Gynecology and Public Health at the University of South Florida. He also serves as an EVP at Tampa General Hospital. Previously he was Dean of The Ohio State University College of Medicine and chaired Ob/Gyn departments at Yale and New York University. He graduated magna cum laude from Brown University, received his M.D. from the University of Pennsylvania and a Master’s in Healthcare Management from the Harvard School of Public Health. Lockwood served his Ob/Gyn residency at Pennsylvania Hospital, a Maternal-Fetal Medicine fellowship at Yale and a post-doctoral research fellowship at Mt. Sinai School of Medicine. His research has been funded by over two decades of federal and foundation support. He has published over 324 peer-reviewed publications (Google h-index of 94; i10-index 358; 34,337 citations [accessed 2/3/25]), 280 editorials, chapters and invited reviews, co-authored 5 monographs and co-edited 6 textbooks, 3 with multiple editions. He is credited with the leading the research team that discovered fetal fibronectin (fFN) as a predictor of impending preterm birth and discovering the role of stromal cell tissue factor expression in regulating endometrial hemostasis and menstruation. He has been elected to the American Association for the Advancement of Science and the U.S. National Academy of Medicine (NAM).
Dr. Charles J. Lockwood is Executive Vice President (EVP) for USF Health, Dean of the Morsani College of Medicine and Professor of Obstetrics & Gynecology and Public Health at the University of South Florida. He also serves as an EVP at Tampa General Hospital. Previously he was Dean of The Ohio State University College of Medicine and chaired Ob/Gyn departments at Yale and New York University. He graduated magna cum laude from Brown University, received his M.D. from the University of Pennsylvania and a Master’s in Healthcare Management from the Harvard School of Public Health. Lockwood served his Ob/Gyn residency at Pennsylvania Hospital, a Maternal-Fetal Medicine fellowship at Yale and a post-doctoral research fellowship at Mt. Sinai School of Medicine. His research has been funded by over two decades of federal and foundation support. He has published over 324 peer-reviewed publications (Google h-index of 94; i10-index 358; 34,337 citations [accessed 2/3/25]), 280 editorials, chapters and invited reviews, co-authored 5 monographs and co-edited 6 textbooks, 3 with multiple editions. He is credited with the leading the research team that discovered fetal fibronectin (fFN) as a predictor of impending preterm birth and discovering the role of stromal cell tissue factor expression in regulating endometrial hemostasis and menstruation. He has been elected to the American Association for the Advancement of Science and the U.S. National Academy of Medicine (NAM).